市场调查报告书
商品编码
1558343
2030 年行动医疗应用市场预测:按产品类型、平台、设备、技术、应用程式、最终用户和地区进行的全球分析mHealth Apps Market Forecasts to 2030 - Global Analysis By Product Type (Medical Apps, Fitness Apps and Other Product Types), Platform, Device, Technology, Application, End User and By Geography |
根据 Stratistics MRC 的数据,2024 年全球行动医疗应用市场规模为 378 亿美元,预计在预测期内将以 16.9% 的复合年增长率增长,到 2030 年达到 966 亿美元。
行动医疗应用程式是一款支援医疗保健服务和资讯的行动应用程式。提供健康资料收集、疾病管理、健康教育、远端医疗、健康监测等多种健康相关功能。行动医疗应用程式的好处包括增加可近性、提高病人参与、增加便利性和成本效益。这些应用程式可以帮助管理慢性病、提供健康教育、实现远端咨询以及追踪健身目标。它也减少了亲自就诊的需要。
根据《行动经济2023》报告,智慧型手机普及率预计在2022年达到76%,2030年达到92%。
健康监测需求增加
糖尿病、高血压和心臟病等慢性病的盛行率不断上升,需要透过行动医疗应用程式进行持续的健康监测。这些工具可帮助患者追踪生命征象、管理症状并更有效地管理治疗。预防性医疗保健也变得越来越重要,行动医疗应用程式可以追踪健身、营养、睡眠和整体健康。
网路威胁的有吸引力的目标
行动医疗应用程式容易受到网路犯罪分子的攻击,从而导致未授权存取、身分盗窃、财务损失和隐私侵犯。网路攻击可能会损害健康资料的完整性,导致临床测量结果被操纵、误诊和不适当的治疗。受害者会经历焦虑、创伤和脆弱,这可能会使现有的心理健康状况恶化。因此,行动医疗应用程式必须保持警惕,保护敏感的健康资料。
行动订阅和网路普及率的增加
行动医疗应用程式正在扩大其覆盖范围,涵盖农村和服务不足的人群。这种可访问性可以实现即时远端患者监护,提高护理品质并促进及时干预。智慧型手机和网路存取的普及导致行动医疗应用程式下载量激增,达到 37 亿次,显示数位医疗产业的收益显着增长。这种利用率的成长对于慢性病管理特别有益。
发展中地区的技术壁垒
新兴市场中的数位落差以及设备和连接分布的不平等阻碍了行动医疗应用程式的采用,限制了潜在的用户群和市场成长。这引起了人们对公平医疗保健服务的担忧。此外,卫生系统准备不足以及行动医疗应用程式与现有医疗保健系统之间缺乏互通性进一步阻碍了采用。这些挑战加剧了数位鸿沟,并阻碍了行动医疗解决方案的有效性和扩充性。
COVID-19 的影响
疫情导致远距医疗需求激增,行动医疗应用程式对于症状追踪、远端医疗咨询和慢性病管理已变得至关重要。政府和医疗机构提高了对这些应用程式的认识,并促进了公众对它们的采用。这场危机改变了人们对数位医疗技术的看法,使它们对医疗保健提供者和患者来说更容易接受和必要,并可能影响未来的医疗保健服务模式。
医疗应用程式行业预计将在预测期内成为最大的行业
医疗应用程式预计在预测期内将成长最快,因为它们透过远端监控、用药提醒和健康追踪来协助慢性病管理。慢性病的增加将推动对行动医疗解决方案的需求。医疗应用程式还使用户能够控制自己的健康,并透过远端医疗咨询和健康追踪等功能带来更好的健康结果,从而提高用户参与度。
预计慢性病管理领域在预测期内的复合年增长率最高。
慢性病需要自我管理工具,例如用药提醒、症状追踪和健康资料登录,导致应用程式使用量增加和市场成长。行动医疗应用程式正在扩展到包括糖尿病、高血压和心血管问题等疾病,近一半的可用应用程式是针对这些疾病设计的。
由于行动使用量和医疗保健支出的增加、5G 网路的成长以及政府措施和资金的增加,预计北美将在预测期内占据最大的市场占有率。根据世界银行统计,2022年北美地区人均国民卫生支出约1,1,076.74美元。此外,该地区慢性病盛行率的上升和老年人口的增加预计将推动市场成长。
在亚太地区,慢性病和感染疾病发病率不断上升、医疗保健成本不断上升、医院服务管理效率低下以及老年人口不断增加,正迫使政府和医疗保健提供者开发新的医疗保健服务模式,预计该模式将在本世纪达到最高的复合年增长率。例如,2024年1月,京东医疗在其应用程式中推出了新的养老频道,为满足中国老龄化人口的各种医疗需求提供综合平台。
According to Stratistics MRC, the Global mHealth Apps Market is accounted for $37.8 billion in 2024 and is expected to reach $96.6 billion by 2030 growing at a CAGR of 16.9% during the forecast period. mHealth Apps are mobile applications that support healthcare services and information. They offer various health-related functionalities, such as health data collection, disease management, health education, telemedicine, and health monitoring. Benefits of mHealth apps include increased accessibility, improved patient engagement, enhanced convenience, and cost-effectiveness. These apps help manage chronic conditions, provide health education, enable remote consultations, and track fitness goals. They also reduce the need for in-person healthcare visits.
According to the Mobile Economy 2023 report, smartphone penetration was at 76% in 2022 and is predicted to reach 92% by 2030.
Increased demand for health monitoring
The increasing prevalence of chronic diseases like diabetes, hypertension, and heart disease necessitates continuous health monitoring through mHealth apps. These tools help patients track vital signs, manage symptoms, and manage treatment more effectively. Preventive healthcare is also gaining importance, with mHealth apps tracking fitness, nutrition, sleep, and overall wellness.
Attractive targets for cyber threats
mHealth apps are vulnerable to cybercriminals, leading to unauthorized access to personal health information (PHI), identity theft, financial loss, and privacy violations. Cyberattacks can compromise health data integrity, causing manipulated clinical measurements, misdiagnoses, and inappropriate treatments. Victims may experience anxiety, trauma, and vulnerability, which can exacerbate existing mental health conditions. Therefore, mHealth apps must be vigilant to protect sensitive health data.
Increase in mobile subscriptions and internet penetration
mHealth apps have expanded their reach, reaching underserved populations in rural areas. This accessibility allows for real-time remote patient monitoring, improving care quality and facilitating timely interventions. The proliferation of smartphones and internet access has led to a surge in mHealth app downloads, reaching 3.7 billion, indicating significant revenue growth in the digital health sector. This growth in usage is particularly beneficial for chronic disease management.
Technological barriers in developing regions
The digital divide and unequal distribution of devices and connectivity in developing regions hinder the widespread use of mobile health apps, limiting their potential user base and market growth. This raises concerns about equitable healthcare delivery. Additionally, inadequate health system readiness and lack of interoperability between mHealth apps and existing healthcare systems further hinder adoption. These challenges contribute to the digital divide and hinder the effectiveness and scalability of mHealth solutions.
Covid-19 Impact
The pandemic led to a surge in demand for remote healthcare, with mHealth apps becoming crucial for symptom tracking, telemedicine consultations, and managing chronic conditions. Governments and health organizations promoted these apps to raise awareness and encourage public adoption. The crisis altered perceptions of digital health technologies, making them more acceptable and necessary for healthcare providers and patients, potentially impacting future healthcare delivery models.
The medical apps segment is expected to be the largest during the forecast period
The medical apps is expected to be the largest during the forecast period as they aid in chronic disease management through remote monitoring, medication reminders, and health tracking. The rise in chronic conditions drives demand for mHealth solutions. Medical apps also boost user engagement by empowering users to take control of their health, leading to better health outcomes through features like telemedicine consultations and health tracking.
The chronic disease management segment is expected to have the highest CAGR during the forecast period
The chronic disease management segment is expected to have the highest CAGR during the forecast period as chronic diseases demand self-management tools like medication reminders, symptom tracking, and health data logging, leading to increased app usage and market growth. mHealth apps have expanded to include diseases like diabetes, hypertension, and cardiovascular issues, with nearly half of available apps designed for these conditions.
North America is projected to hold the largest market share during the forecast period owing to increasing mobile usage & healthcare expenditure, growing 5G networks, and rising number of government initiatives & funding are driving the regional market growth. As per the World Bank statistics, the per capita national health expenditure in North America in 2022 was about USD 11,076.74. Furthermore, rising chronic disease prevalence and increasing geriatric population in the region are expected to support market growth.
Asia Pacific is projected to witness the highest CAGR over the forecast period owing to increasing incidence of chronic & infectious diseases, rising healthcare expenditure, ineffective hospital service management, and a growing elderly population, are compelling governments & healthcare providers to develop new healthcare delivery models. For instance, in January 2024, JD Health introduced a new elderly care channel on its app to provide a comprehensive platform for the various healthcare needs of China's aging population.
Key players in the market
Some of the key players in mHealth Apps market include Abbott, AirStrip Technologies, Inc., Apple Inc, AstraZeneca, AT&T, Boston Scientific Corporation, Fitbit Inc, Google Inc., Johnson & Johnson Services, Inc., Livongo Health, Novartis AG, Omada Health, Inc., Omron Healthcare, Inc, Orange, Pfizer Inc., Qualcomm Technologies, Inc., Samsung Electronics Co. Ltd., Sanofi, Teladoc Health, Inc. and Veradigm LLC
In September 2024, Abbott announced U.S. availability of Lingo(TM), the company's first continuous glucose monitoring system available without a prescription. Lingo is based on Abbott's world-leading FreeStyle Libre(R) continuous glucose monitoring technology1, now used by more than 6 million people with diabetes globally1.
In August 2024, Abbott announced the expansion of its Pure Bliss(TM) by Similac(R) line of organic, and European-made infant formulas that give parents a variety of products to meet specific formula preferences.
In June 2024, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.